		Observations	1943	Patient ID 1410 corresponds to a duplicate registration for which no	n data was collected and therefore excluded
Member Type	DATA	Variables		Unless otherwise indicated, blank fields indicate missing values	data was conceted and therefore excided
.vieinzei iype	27.117	Variables		Note: Primary analysis includes all cases	
List of Variables a	and Attributes			, , , , , , , , , , , , , , , , , , , ,	
#	Variable	Туре	Len	Label	Codes
	uid	Num		blinded ID (integer)	
2	blindid	Char	18	Blinded treatment code prepended with study ID	
3	ethnicity	Num	3	NCI Ethnicity	1=Hispanic, 2=Non-Hispanic, 11=Institution Refusal 12=Not Reported
4	ncirace	Num	3	NCI Race	1=white, 3=African-American, 4=Asian, 5=Hawaiian/Pacific Islander, 6=Native American, 11=Other
	cancl	Num		Reason Withdrew before Treatment	blank = did not withdraw, 1=patient refused treatment, 3=ineligible, 8=other, 11=progressed before treatment
6	arm	Char	1	Treatment Arm	A=Sunitinib, B=Sorafenib, C=Placebo
7	OFF_TX_REAS	Num		Off Treatment Reason	See below
8	ps	Num	3	Performance Status Prior to Surgery	
			_		
	dosegrp	Num		Starting Dose Group	1=Started at Full Dose, 2=Started at Reduced Dose
	cycles age	Num Num		Total Cycles Age (Yrs)	
	pathtstgnum	Num	1	Path T Stage Number	1 = T1, 2 = T2, 3 = T3, 4 = T4
	pathnstg	Char		Path N Stage	0 = N0, 1 = N1, 2 = N2, X = NX
	pathmstg	Char		Path M Stage	0 = M0, 1 = M1, X = MX
			_	, , , , , , , , , , , , , , , , , , ,	· ·
15	fuhrman	Num	3	Fuhrman Grade	1 = Grade 1, 2 = Grade 2, 3 = Grade 3, 4 = Grade 4
16	prim_surg_type	Num	3	Type of Nephrectomy (Radical vs Partial)	1=Radical, 2=Partial
17	dose_per_prot	Num	3	Full Prot Dose at Cycle 3?	0=no, 1=yes
	dead	Num		Survival Status (1=deceased)	0=alive/censored, 1=dead
19	dfsevent	Num	3	Disease-Free Survival Event	0=no, 1=yes
20	dfsmos	Num	8	Disease-Free Survival Time (Months)	
24	firstor	Numa	2	Time of First DEC French	1=Recurrence, 2=Second Primary, 3=Death without Recurrence or Second Primary, 4=Metastatic Disease at Diagnosis, 0=Censored
	firstev ajccstage	Num		Type of First DFS Event AJCC Stage	1 = Stage 1, 2 = Stage 2, 3 = Stage 3, 4 = Stage 4
	sex	Num		Sex	1=male, 2=female
23	36%	Num	3	364	Risk Category: 1=Intermediate High Risk,2=Very
24	var1	Char	1	STRATIFICATION VAR 1	High Risk
	var2	Char		STRATIFICATION VAR 2	Histology: 1=Clear Cell, 2=Other
	var3	Char		STRATIFICATION VAR 3	Performance Status: 1=PS 0, 2=PS 1
	var4	Char		STRATIFICATION VAR 4	Surgical Approach: 1=Laparoscopic, 2=Open
28	sorafmgp	Num	6	Sum of Soraf/Pbo Doses Prescribed Day 1 Each Cycle (mg)	
29	sorafmg	Num		Sum of Soraf/Pbo Doses Recorded as Taken by Pt (mg)	
30	sorafavg	Num	8	Total Soraf/Pbo Dose Taken Divided by Number of Cycles (mg)	
31	sorafpct	Num	8	Percent of Prescribed Soraf/Pbo Dose Taken	
32	sunitmgp	Num	8	Sum of Sunit/Pbo Doses Prescribed Day 1 Each Cycle (mg)	
33	sunitmg	Num	8	Sum of Sunit/Pbo Doses Recorded as Taken by Pt (mg)	
34	sunitavg	Num		Total Sunit/Pbo Dose Taken Divided by Number of Cycles (mg)	
	sunitpct	Num		Percent of Prescribed Sunit/Pbo Dose Taken	
	recursite	Num		Site of Recurrence	See below
37	txdurmos	Num	8	Treatment Duration (Months)	1=Clear Cell, 2=Papillary, 3=Chromophobe, 4=Mixed, >25% Clear, 5=Mixed, <25% Clear,
38	renal histol	Num	3	Histology	6=Unclassified
	sarco_feat_yn	Num		Sarcomatoid Features?	1=No, 2=Yes
	surg_meth	Num		Surgical Approach per Surgeon (Open vs Lap)	1=Open, 2=Laparoscopic
41	survmos	Num	8	Survival Time (Months)	
42	toxflag	Num	8	Toxicity Assessed Flag	1=Included in Safety Analysis, 0 otherwise
Formats:					
Off Treatment Re					
=Complete per Protocol					1
=Disease Progression					<u> </u>
	'S				<u> </u>
3=Adverse Events					
3=Adverse Events 4=Death					
3=Adverse Events 4=Death 5=Patient Withdr	rawal/Refusal				
3=Adverse Events 4=Death 5=Patient Withdr 6=Alternative The	rawal/Refusal erapy				
3=Adverse Events 4=Death 5=Patient Withdr	rawal/Refusal erapy				

Sites of Recurrence			
1=Lung			
2=Liver			
3=Central Nervous System			
4=Subcutaneous/Lymph Node			
5=Skeletal			
6=Renal Bed			
7=Other Organs			
8=Other			
9=Unknown			